ArticleEndocrine-related cancer2013
FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.
Article in Endocrine-related cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- TRP matters: a pilot study on expression of mRNA in the parotid glands and their benign tumors.Biochemistry and biophysics reports · 2026Article
- TRP channels and cancer modulation: a voyage beyond metabolic reprogramming, oxidative stress and the advent of nanotechnologies in targeted therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- TRPC3 signalling contributes to the biogenesis of extracellular vesicles.Journal of extracellular biology · 2024Article
- Calcium signals and potential therapy targets in ovarian cancer (Review).International journal of oncology · 2023Review
- Expression of canonical transient receptor potential channels in U-2 OS and MNNG-HOS osteosarcoma cell lines.Oncology letters · 2021Article
- A novel strategy for treating cancer: understanding the role of CaExploration of targeted anti-tumor therapy · 2021Review
- Review
- DEAD-Box Helicase 4 (Ddx4)International journal of molecular sciences · 2020Article
- Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase.Scientific reports · 2020Article
- Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3.Journal of ovarian research · 2020Article
- Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer.American journal of translational research · 2020Review
- Calcium Permeable Channels in Cancer Hallmarks.Frontiers in pharmacology · 2020Review
- Article
- Estrogen Enhances Endometrial Cancer Cells Proliferation by Upregulation of Prohibitin.Journal of Cancer · 2019Article
- Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.Oncogene · 2018Article
- FSH receptor binding inhibitor impacts K-Ras and c-Myc of ovarian cancer and signal pathway.Oncotarget · 2018Article
- Leptin OB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells.Journal of biomedical science · 2017Article
- Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.International urology and nephrology · 2017Article
- Article
- Role of TRP ion channels in cancer and tumorigenesis.Seminars in immunopathology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Recent studies have suggested that FSH plays an important role in ovarian epithelial carcinogenesis. We demonstrated that FSH stimulates the proliferation and invasion of ovarian cancer cells, inhibits apoptosis and facilitates neovascularisation. Our previous work has shown that transient receptor potential channel C3 (TRPC3) contributes to the progression of human ovarian cancer. In this study, we further investigated the interaction between FSH and TRPC3. We found that FSH stimulation enhanced the expression of TRPC3 at both the mRNA and protein levels. siRNA-mediated silencing of TRPC3 expression inhibited the ability of FSH to stimulate proliferation and blocked apoptosis in ovarian cancer cell lines. FSH stimulation was associated with the up-regulation of TRPC3, while also facilitating the influx of Ca(2)(+) after treatment with a TRPC-specific agonist. Knockdown of TRPC3 abrogated FSH-stimulated Akt/PKB phosphorylation, leading to decreased expression of downstream effectors including survivin, HIF1-α and VEGF. Ovarian cancer specimens were analysed for TRPC3 expression; higher TRPC3 expression levels correlated with early relapse and worse prognosis. Association with poor disease-free survival and overall survival remained after adjusting for clinical stage and grade. In conclusion, TRPC3 plays a significant role in the stimulating activity of FSH and could be a potential therapeutic target for the treatment of ovarian cancer, particularly in postmenopausal women with elevated FSH levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.